A multi-center, real-life experience on liquid biopsy practice for EGFR testing in non-small cell lung cancer (NSCLC) patients

Francesco Cortiula; Giulia Pasello; Alessandro Follador; Giorgia Nardo; Valentina Polo; Elisa Scquizzato; Alessandro Del Conte; Marta Miorin; Petros Giovanis; Alessandra D’Urso; Salvator Girlando; Giulio Settanni; Vincenzo Picece; Antonello Veccia; Carla Corvaja; Stefano Indraccolo; Giovanna De Maglio

doi:10.3390/diagnostics10100765

A multi-center, real-life experience on liquid biopsy practice for EGFR testing in non-small cell lung cancer (NSCLC) patients

Francesco Cortiula, Giulia Pasello, Alessandro Follador, Giorgia Nardo, Valentina Polo, Elisa Scquizzato, Alessandro Del Conte, Marta Miorin, Petros Giovanis, Alessandra D’Urso, Salvator Girlando, Giulio Settanni, Vincenzo Picece, Antonello Veccia, Carla Corvaja, Stefano Indraccolo, Giovanna De Maglio

Research output: Contribution to journal › Article › peer-review

Abstract

Background: circulating tumor DNA (ctDNA) is a source of tumor genetic material for EGFR testing in NSCLC. Real-word data about liquid biopsy (LB) clinical practice are lacking. The aim of the study was to describe the LB practice for EGFR detection in North Eastern Italy. Methods: we conducted a multi-regional survey on ctDNA testing practices in lung cancer patients. Results: Median time from blood collection to plasma separation was 50 min (20–120 min), median time from plasma extraction to ctDNA analysis was 24 h (30 min–5 days) and median turnaround time was 24 h (6 h–5 days). Four hundred and seventy five patients and 654 samples were tested. One hundred and ninety-two patients were tested at diagnosis, with 16% EGFR mutation rate. Among the 283 patients tested at disease progression, 35% were T790M+. Main differences in LB results between 2017 and 2018 were the number of LBs performed for each patient at disease progression (2.88 vs. 1.2, respectively) and the percentage of T790M+ patients (61% vs. 26%).

Original language	English
Article number	765
Number of pages	7
Journal	Diagnostics
Volume	10
Issue number	10
DOIs	https://doi.org/10.3390/diagnostics10100765
Publication status	Published - Oct 2020

ASJC Scopus subject areas

Clinical Biochemistry

Access to Document

10.3390/diagnostics10100765

Cite this

Cortiula, F., Pasello, G., Follador, A., Nardo, G., Polo, V., Scquizzato, E., Conte, A. D., Miorin, M., Giovanis, P., D’Urso, A., Girlando, S., Settanni, G., Picece, V., Veccia, A., Corvaja, C., Indraccolo, S., & Maglio, G. D. (2020). A multi-center, real-life experience on liquid biopsy practice for EGFR testing in non-small cell lung cancer (NSCLC) patients. Diagnostics, 10(10), [765]. https://doi.org/10.3390/diagnostics10100765

Cortiula, F, Pasello, G, Follador, A, Nardo, G, Polo, V, Scquizzato, E, Conte, AD, Miorin, M, Giovanis, P, D’Urso, A, Girlando, S, Settanni, G, Picece, V, Veccia, A, Corvaja, C, Indraccolo, S & Maglio, GD 2020, 'A multi-center, real-life experience on liquid biopsy practice for EGFR testing in non-small cell lung cancer (NSCLC) patients', Diagnostics, vol. 10, no. 10, 765. https://doi.org/10.3390/diagnostics10100765

@article{e395afb6cfe3404db9539d111ef941f0,

title = "A multi-center, real-life experience on liquid biopsy practice for EGFR testing in non-small cell lung cancer (NSCLC) patients",

abstract = "Background: circulating tumor DNA (ctDNA) is a source of tumor genetic material for EGFR testing in NSCLC. Real-word data about liquid biopsy (LB) clinical practice are lacking. The aim of the study was to describe the LB practice for EGFR detection in North Eastern Italy. Methods: we conducted a multi-regional survey on ctDNA testing practices in lung cancer patients. Results: Median time from blood collection to plasma separation was 50 min (20–120 min), median time from plasma extraction to ctDNA analysis was 24 h (30 min–5 days) and median turnaround time was 24 h (6 h–5 days). Four hundred and seventy five patients and 654 samples were tested. One hundred and ninety-two patients were tested at diagnosis, with 16% EGFR mutation rate. Among the 283 patients tested at disease progression, 35% were T790M+. Main differences in LB results between 2017 and 2018 were the number of LBs performed for each patient at disease progression (2.88 vs. 1.2, respectively) and the percentage of T790M+ patients (61% vs. 26%).",

author = "Francesco Cortiula and Giulia Pasello and Alessandro Follador and Giorgia Nardo and Valentina Polo and Elisa Scquizzato and Conte, {Alessandro Del} and Marta Miorin and Petros Giovanis and Alessandra D{\textquoteright}Urso and Salvator Girlando and Giulio Settanni and Vincenzo Picece and Antonello Veccia and Carla Corvaja and Stefano Indraccolo and Maglio, {Giovanna De}",

year = "2020",

month = oct,

doi = "10.3390/diagnostics10100765",

language = "English",

volume = "10",

journal = "Diagnostics",

issn = "2075-4418",

publisher = "MDPI AG",

number = "10",

}

TY - JOUR

T1 - A multi-center, real-life experience on liquid biopsy practice for EGFR testing in non-small cell lung cancer (NSCLC) patients

AU - Cortiula, Francesco

AU - Pasello, Giulia

AU - Follador, Alessandro

AU - Nardo, Giorgia

AU - Polo, Valentina

AU - Scquizzato, Elisa

AU - Conte, Alessandro Del

AU - Miorin, Marta

AU - Giovanis, Petros

AU - D’Urso, Alessandra

AU - Girlando, Salvator

AU - Settanni, Giulio

AU - Picece, Vincenzo

AU - Veccia, Antonello

AU - Corvaja, Carla

AU - Indraccolo, Stefano

AU - Maglio, Giovanna De

PY - 2020/10

Y1 - 2020/10

N2 - Background: circulating tumor DNA (ctDNA) is a source of tumor genetic material for EGFR testing in NSCLC. Real-word data about liquid biopsy (LB) clinical practice are lacking. The aim of the study was to describe the LB practice for EGFR detection in North Eastern Italy. Methods: we conducted a multi-regional survey on ctDNA testing practices in lung cancer patients. Results: Median time from blood collection to plasma separation was 50 min (20–120 min), median time from plasma extraction to ctDNA analysis was 24 h (30 min–5 days) and median turnaround time was 24 h (6 h–5 days). Four hundred and seventy five patients and 654 samples were tested. One hundred and ninety-two patients were tested at diagnosis, with 16% EGFR mutation rate. Among the 283 patients tested at disease progression, 35% were T790M+. Main differences in LB results between 2017 and 2018 were the number of LBs performed for each patient at disease progression (2.88 vs. 1.2, respectively) and the percentage of T790M+ patients (61% vs. 26%).

AB - Background: circulating tumor DNA (ctDNA) is a source of tumor genetic material for EGFR testing in NSCLC. Real-word data about liquid biopsy (LB) clinical practice are lacking. The aim of the study was to describe the LB practice for EGFR detection in North Eastern Italy. Methods: we conducted a multi-regional survey on ctDNA testing practices in lung cancer patients. Results: Median time from blood collection to plasma separation was 50 min (20–120 min), median time from plasma extraction to ctDNA analysis was 24 h (30 min–5 days) and median turnaround time was 24 h (6 h–5 days). Four hundred and seventy five patients and 654 samples were tested. One hundred and ninety-two patients were tested at diagnosis, with 16% EGFR mutation rate. Among the 283 patients tested at disease progression, 35% were T790M+. Main differences in LB results between 2017 and 2018 were the number of LBs performed for each patient at disease progression (2.88 vs. 1.2, respectively) and the percentage of T790M+ patients (61% vs. 26%).

UR - http://www.scopus.com/inward/record.url?scp=85092236157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85092236157&partnerID=8YFLogxK

U2 - 10.3390/diagnostics10100765

DO - 10.3390/diagnostics10100765

M3 - Article

AN - SCOPUS:85092236157

VL - 10

JO - Diagnostics

JF - Diagnostics

SN - 2075-4418

IS - 10

M1 - 765

ER -

A multi-center, real-life experience on liquid biopsy practice for EGFR testing in non-small cell lung cancer (NSCLC) patients

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this